7 clinical trials found.
-
A PHASE 1/2 OPEN-LABEL DOSE-ESCALATION SAFETY AND TOLERABILITY STUDY OF NC410 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
The purpose of the study is to determine the safety and tolerability of NC410, and to assess the preliminary efficacy of NC410 in subjects with ...Phase
-
A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor Alpha (FolRa) Antibody-Drug Conjugate (ADC) in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
The purpose of the study is to determine the safety and efficacy of STRO-002, which is a antibody drug conjugate (ADC) given intravenously every 3 ...Phase
-
A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of the study drug CPI-0209 as monotherapy and in combination with irinotecan in ...Phase
-
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
The purpose of the study is to determine how well tucatinib works with trastuzumab for solid tumors that make either more HER2 or a different ...Phase
-
A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
The purpose of the study is to determine the safety and tolerability of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every ...Phase
-
A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.
The study is being done to look at: • The possible side effects, safety and tolerability of CX-2029 • The highest dose of CX-2029 that can be ...Phase
-
A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug ...Phase
